Articles tagged with Drug Studies
Insilico Medicine's inClinico platform uses generative AI to predict Phase II to Phase III clinical trial success with an accuracy of 79%. The tool has been validated in various studies and can provide valuable insights for investors and biotech/pharma companies.
A large head-to-head comparison study of the Moderna and Pfizer-BioNTech vaccines found that the Moderna vaccine was associated with a slightly lower risk of adverse events for older adults. The study also showed that the Moderna vaccine was linked to a 4% lower risk of pulmonary embolism and a 15% lower risk of diagnosed COVID-19.
Researchers propose disease-oriented dosing of rapamycin to delay age-related diseases and increase lifespan. By decelerating early development of these diseases, rapamycin may help individuals live longer.
Researchers found that translating consent documents can discourage investigators from recruiting patients with limited English proficiency, contributing to low rates of participation from underrepresented groups. By relieving investigators of these costs, studies can become more inclusive and results more accurate and generalizable.
A new drug formulation designed for treating children with HIV has shown safety, tolerability, and effectiveness in a study published in The Lancet HIV. The formulation contains three medications and was found to suppress HIV levels below 200 copies/mL in 98% of participants.
Researchers developed a targeted chemotherapy that selectively disrupts DNA replication and repair in cancer cells, leaving healthy cells unaffected. The investigational small molecule AOH1996 has been effective in treating various types of solid tumors in preclinical research.
The NIH has launched phase 2 clinical trials to evaluate at least four potential treatments for long COVID, including drugs, biologics, and therapies. These trials aim to identify effective treatments swiftly by evaluating multiple treatments simultaneously.
Researchers from Sahmyook University found that phyllodulcin, a natural sweetener found in hydrangeas, can efficiently inhibit amyloid beta (Aβ) aggregation and dissociate its aggregates in an animal model study. The study suggests that phyllodulcin may be useful in delaying the onset and progression of Alzheimer's disease.
A first-in-human study demonstrates the efficacy of a novel PRMT5 inhibitor, JNJ-64619178, in treating advanced solid tumors. The treatment showed manageable dose-dependent toxicity and achieved preliminary antitumor activity in patients with various cancer types.
Researchers developed new methods for detecting drug-induced hepatotoxicity using 3D cell cultures and mass spectrometry imaging, identifying biomarkers and effective interventions. A zeolite-based protein corona method was also used to characterize plasma proteins, enabling the identification of low-abundance proteins and their potent...
Primary care physicians face challenges in prescribing medications for alcohol use disorder (MAUD), citing negative personal beliefs about treatment effectiveness and patient adherence. Despite this, they selectively prescribe MAUD to motivated patients with severe AUD or receiving concurrent treatments, highlighting the need for incre...
A Dutch study found that higher levels of personal continuity among older patients are associated with reduced potentially inappropriate prescriptions and prescribing omissions. The researchers analyzed routine care data from over 25,000 patients and discovered that increased personal continuity led to a significant decrease in PIPs, p...
The latest Alzheimer's drug, donanemab, has shown encouraging results in slowing cognitive decline by 35% compared to placebo in patients with low-to-intermediate levels of tau. However, its effectiveness is limited for those with more advanced disease, and risks include serious side effects such as amyloid-related imaging abnormalities.
A team of medical leaders recommends a sustainably funded public-private partnership to combat misinformation, citing challenges faced by the TIOS-VY organization. The American College of Physicians calls for modernizing public health infrastructure, including increased funding and addressing disinformation, especially on social media.
Researchers have discovered a mechanism leading to resistance in luminal breast cancer and propose using the approved osteoporosis drug denosumab to block RANK protein, promoting effectiveness of CDK4/6 inhibitors. This could lead to new treatment options for patients with metastatic breast cancer.
A randomized controlled trial funded by NIH found low-dose atropine eyedrops to be no better than placebo in slowing myopia progression among US children. The study contradicts previous East Asian trials that showed a benefit from 0.01% atropine. Further research is needed to identify an optimal approach for preventing high myopia.
A low-cost version of ketamine has shown strong results in treating treatment-resistant depression, with over 20% participants achieving total remission and a third experiencing symptom improvement. The study's findings bring definitive evidence to the field, which can be more affordable than existing treatments.
A new study led by Sandra Casimiro and Luís Costa found a promising molecular target, the RANK signaling pathway, that could be used in combination with standard care to avoid resistance to treatment in metastatic breast cancer. High levels of RANK in cancer cells are associated with resistance to treatment with CDK4/6 inhibitors.
A new UCF study found that insurance coverage of extended-release buprenorphine injections is lacking, with only 46% of commercial plans and 19% of Medicare Advantage plans covering it. Prior-authorization requirements also pose a barrier to access, particularly for Medicaid plans.
Researchers at Nanyang Technological University discover ponatinib, an existing cancer drug, can block key steps in alternative lengthening of telomeres (ALT) mechanism. This could lead to new treatment options for ALT cancers, which currently lack targeted therapies.
A comprehensive review of biochemical markers for bone fragility in diabetes identifies low bone turnover and alterations in bone quality as key factors. The study suggests that glycemic control, AGEs, and serum IGF-1 may have predictive value for fracture risk in patients with diabetes.
Researchers found that a triple combination therapy of elexacaftor, tezacaftor, and ivacaftor improves lung function and reduces inflammation in patients with cystic fibrosis. The treatment's positive effects last over 12 months, offering hope for better management of the disease.
Research leaders collaborate with organizations and regulators to develop digital tools for Parkinson's clinical trials. The Digital Drug Development Tools initiative accelerates the regulatory endorsement of these tools, enabling more objective and patient-centered measures.
Researchers at Johns Hopkins Medicine have identified a new target for treating HIV infection by blocking the neutral sphingomyelinase-2 (nSMase2) enzyme. Inhibiting this enzyme can prevent HIV replication and kill infected cells, offering a promising therapeutic approach.
A clinical trial of a three-month tuberculosis treatment regimen has been closed due to high rates of unfavorable outcomes. Participants who received the investigational treatment experienced ongoing or recurring TB at rates above thresholds set in the study protocol.
A new clinical trial has found luspatercept to be significantly more effective than epoetin alfa in treating MDS anaemia, reducing the need for blood transfusions. The results have implications for treatment algorithms and may establish luspatercept as a first-line treatment option.
A clinical trial has shown that desmopressin may reduce the risk of death or disability in stroke patients taking antiplatelet drugs. The results support the need for a large-scale trial to determine its effectiveness.
A world-first trial by the University of Sydney found that opioids do not alleviate acute back and neck pain, but may cause harm. The researchers recommend updating treatment guidelines to advise against opioid use for this purpose.
A randomized trial will be conducted to test whether sticking with the initial medication or switching to a different one increases quitting success. The study aims to provide guidance for clinicians on handling relapses and may explore the effectiveness of e-cigarettes as an alternative to traditional cigarettes.
A new study found that higher doses of oral semaglutide improved regulation of blood sugar levels and weight loss compared to lower doses. Participants who received the 25mg and 50mg doses lost an average of 17.5 pounds, nearly twice as much weight loss as those who took the lowest dose.
A randomized controlled trial found that time-restricted eating produced similar weight loss results to traditional calorie counting in a racially diverse population of adults with obesity. Participants who engaged in 8-hour time-restricted eating had improved insulin sensitivity compared to those in the control group.
Peruvoside has been discovered to prevent up to 12 medically important viruses, including SARS-CoV-2, Hand, Foot and Mouth Disease (HFMD), and Influenza. The compound acts on GBF1 protein, disabling its functionality and stopping virus production.
A new analysis found that expanding Medicaid eligibility to more people improved patient outcomes, prevention measures, and screening access. The study suggests that increasing health insurance coverage results in better health outcomes for those with heart disease.
COPD patients treated with dupilumab experienced rapid and sustained improvements in disease, as measured by reduced acute exacerbations, better lung function, and improved quality of life. This is the first biologic to show clinical outcomes improvement in COPD.
Researchers found that leukemia cells use messenger particles to navigate and release molecular cargo at distant sites, driving cancer metastasis. A potential therapeutic strategy involves targeting these particles with an antibody drug that blocks E-selectin activity.
A post-hoc analysis of the ASPREE trial found that low-dose aspirin was associated with a 20% increased incidence of anemia and decline in ferritin levels in healthy older adults. The study recommends periodic monitoring of hemoglobin for patients taking aspirin.
A study by Martin-Luther-University Halle-Wittenberg found a link between high levels of IGF2BP2 and faster-growing bowel cancer tumours with chemotherapy resistance. The protein's role in cell growth and metabolism may lead to the development of new diagnostic procedures and therapeutic strategies.
Researchers from McGill University and Ontario Tech University examine the drivers of specialty drug diffusion. They propose a framework that suggests clinical studies affect the diffusion through a multi-stage scientific evidence production process. The study finds that marketing activities have no significant effect on prescriptions.
The use of psychedelics in mental health treatment is gaining traction, but concerns about patient safety and regulation need to be addressed. Psychedelic-assisted therapy shows promise in treating conditions like depression and PTSD, but more research is needed on dosages, settings, and guidelines.
The Better Together trial partners with community organizations and sites to provide buprenorphine treatment, reducing distance for patients and offering peer support in familiar environments. Researchers aim to address barriers such as stigma, misunderstandings about addiction, and bias against certain treatments.
A new study found that the serotonin booster prucalopride increased functional brain connectivity in healthy adults, particularly between cognitive networks. The results suggest that prucalopride may improve cognitive function and have therapeutic potential for depression patients.
A machine-learning study has found that individual characteristics, including age and weight, determine which drug combinations most effectively reduce COVID-19 recurrence rates. The study used real-world data from a hospital in China and identified unique treatment combinations for different demographic groups.
A powerful new stem cell technique has enabled large-scale studies of the relationship between human genetics and biology, accelerating research and potential personalized treatments.
A large-scale randomized clinical trial found that metformin prevents the development of long COVID. Over 1,100 participants reported on their symptoms for up to 10 months after initial COVID-19 diagnosis. The study suggests metformin could have significant public health implications as a preventive measure.
A decision analytical model study found that sustained public health interventions can reduce opioid-related overdose deaths. Implementing medications for opioid use disorder and increasing naloxone supply were key factors in reducing death rates.
Young adults' past-year use of non-LSD hallucinogens increased from 3.4% in 2018 to 6.6% in 2021, raising public health concerns. The study found that male and white young adults used these substances more frequently.
A retrospective study found a 24% response rate to Docetaxel among patients with stage IV non-small cell lung cancer who experienced progression on immunotherapy. The median progression-free survival was 3 months, suggesting chemotherapy may still play an important role in treatment after immunotherapy failure.
Researchers at the University of Gothenburg found that semaglutide, a diabetes medication, significantly reduced alcohol intake and relapse-like drinking in rats. This study suggests that semaglutide may be effective in treating alcohol dependence, particularly for individuals with both obesity and diabetes.
Two studies investigate long-term consequences of COVID-19, identifying potential drug targets for treating chronic disease. Researchers found novel pathways in the lungs and immune system that may lead to effective treatment options, including therapies targeting immune dysfunction and mucous cell differentiation.
Researchers at UCSF tested a nitroglycerin patch for treating menopausal women experiencing severe hot flashes. The study found short-term improvements, but benefits did not last past 12 weeks, with some side effects reported.
A supervised hospital walking program has been shown to reduce nursing facility admissions for older adults by lowering the proportion of patients discharged to skilled nursing facilities from 13% to 8%. However, low participation rates and limited impact on length of stay or inpatient falls were noted.
Erdafitinib achieves tumor-agnostic benefits across 16 cancer types, including urothelial, lung, and other cancers. The trial demonstrated a disease control rate of 73.7% and clinical benefit rate of 45.6%, with notable improvements in pancreatic and cholangiocarcinoma patients.
The study found an objective response rate of 61.3% with a median duration of response of 22.1 months in patients with high HER2 expression. The treatment showed promise in a significant unmet area of clinical need, providing a new option for patients with hard-to-treat HER2-positive cancers.
A phase 3 clinical trial by Dana-Farber Cancer Institute has shown vorasidenib significantly prolongs progression-free survival and delays radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma. Treatment with vorasidenib can delay cognitive dysfunction in patients and preserve their quality of life.
A new targeted therapy drug vorasidenib has been shown to extend treatment time without worsening glioma in people with IDH1 and IDH2 mutations. The study suggests a possible new treatment option for slow-growing but deadly brain tumors, delaying chemotherapy and radiation.
A phase I study found significant clinical benefit of the ADC luveltamab tazevibulin in patients with recurrent ovarian cancer expressing high levels of folate receptor alpha, with an overall response rate of 37.5% and a 44% response rate at higher doses.
A Phase II trial led by MD Anderson Cancer Center showed that zanidatamab achieved a 41% confirmed objective response rate and durable responses in HER2-positive biliary tract cancer. This represents the largest study of a HER2-targeted drug in BTC, providing evidence for its potential as a new treatment option.
A retrospective cohort study of over 66,000 older adults found that intensive antihypertensive treatment during hospitalization was linked to greater risk of adverse events. Treating asymptomatic elevated blood pressure in hospitalized patients may not be necessary and could lead to overtreatment.
A new clinical trial found that low-dose atropine eye drops are effective in slowing the progression of nearsightedness in children. The treatment showed significant improvements in limiting eyeglass prescription changes and inhibiting elongation of the eye, with a daily drop in each eye being enough to make a difference.
A study suggests that ketamine nasal spray is a convenient alternative to intravenous infusion for treating refractory chronic migraine. The treatment showed promise in reducing daily headaches and improving quality of life, with most participants reporting 'very effective' results.